Other SGLT-2s in Development
The recent approval of Invokana is exciting, opening the door to a new class of medications that can help people to manage type 2 diabetes, but it was not exactly the only drug on that long road to approval. Take a look at other potential medications that are in various stages of trials and approvals that may join this newest class of oral medications.
Astellas Pharma – Ipragliflozin
- This drug has been filed for marketing approval in Japan and is in the process of completing phase III trials.
- Trials have shown its potential to significantly lower glycated hemoglobin levels (HbA1c) over time as compared to placebo.
Bi/Lilly – Empagliflozin
- This drug is in Phase III of clinical trial process involving over 14,500 patients. There will be a total of 12 clinical trials performed throughout several countries.
- It is said that the companies will present results of the studies at some point in 2013 or 2014.
Chugai (Roche) – Tofogliflozin Hydrate
- According to Chugai Pharma, as of November 2010, this drug is in Phase III of clinical trials.
Lexicon – LX4211
- This drug inhibits both SGLT1 and SGLT2, making it the first of its kind to be introduced in clinical development for diabetes.
- LX4211 will begin Phase III clinical studies in the middle of 2013.
Taisho Pharma – luseogliflozin
- This drug is currently in Phase III of clinical trials.
Bristol-Myers Squibb – Farxiga
- This is a once- daily oral treatment specifically geared toward type 2 diabetes, to be used in conjunction with exercise and a proper diet. This treatment is currently in clinical trials.
Reviewed by James A. Bennett 04/14.
- • Astellas. AVEO and Astellas announce postive findings from TIVO-1 superiority study of tivozanib in first line advanced RCC., http://www.astellas.com/en/corporate/news/pdf/121003_Eg_1.pdf. (PDF) (Accessed 4/11/13.)
- • Lexicon Pharmaceuticals. LX4211, http://www.lexgen.com/pipeline/lx4211.html. (Accessed 4/11/13.)
- • Chugai Pharma USA. Annual report, 2011. http://www.chugai-pharm.co.jp/hc/ss/downloads/eAR2011_12_09.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3DeAR2011_12_09.pdf&blobwhere=1259656736395&ssbinary=true. (PDF) (Accessed 4/11/13.)
- • Theheart.org. FDA approves new diabetes drug, canagliflozin, despite CV concerns, http://www.theheart.org/article/1523789.do. (Accessed 4/11/13.)
- • Drug Discovery & Development Magazine. Lilly, BI submit empagliflozin to FDA, http://www.dddmag.com/news/2013/03/lilly-bi-submit-empagliflozin-fda. (Accessed 4/11/13.)
Surveys Find Adults with Type 2 Diabetes Are More Willing to Take Action to Achieve A1C Targets Quicker than Physicians and Other Medical Professionals Perceive
FDA Votes to Change Jardiance Label to Show Reduction in Heart-Related Deaths
Low Carb vs. High Carb II – My Diabetes Diet Battle Continued
Beary Good Snack Mix Homemade Pickles Cheese and Basil Scones (Dairy) Herb and Oat Crusted Chicken Cheddar Cornbread Honey Glazed Salmon Sweet Potato Biscuits Spinach Salad with Toasted Pine Nut Dressing Tuna-Noodle Casserole Caribbean Style Rice Pilaf
Years before I was diagnosed with type 2 diabetes, The Other Half came out of a doctor's appointment with a diagnosis of "borderline diabetes" and an ADA exchange diet sheet. His health insurance agency followed up on the diagnosis with a glucometer and test strips. After a year or so of trying to follow the diet plan and test his glucose levels, things appeared to be back in "normal" range, and stood there until a couple of years after my own diagnosis. Shortly...